Heartflow, Inc. announced data from the FISH&CHIPS Study at the AHA Scientific Sessions 2025, showing higher TPV stages had a 5x greater risk of major cardiovascular events. The study, evaluating 8,000 patients, validated Heartflow Plaque Staging’s predictive power for heart attacks or cardiovascular death. These findings support personalized treatment decisions above traditional risk factors. Results from the DECIDE Registry showed Heartflow Plaque Analysis led to changes in medical management and decreased cardiac event risk by 15%. Heartflow’s technology uses AI to transform CAD care and provide actionable insights without invasive procedures, impacting nearly 500,000 patients worldwide.

Read more at GlobeNewswire: Late-Breaking Data Reinforce the Prognostic Power